Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tiragolumab Plus Atezolizumab in Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma
NCT05681039Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2023
- Primary completion
- Nov 2026
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tiragolumab and atezolizumab in oral cavity squamous cell carcinoma (OCSCC), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Major Pathological Response Rate. Started Jun 2023; status: active, not recruiting.
02
Drugs
tiragolumabatezolizumab
03
Conditions
oral cavity squamous cell carcinoma (OCSCC)
Beyond the preview
Go deeper on NCT05681039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05681039.